9 Meters Biopharma begins trial for short bowel syndrome treatment
Click Here to Manage Email Alerts
A clinical trial for a new treatment for short bowel syndrome is under way, according to the manufacturer, 9 Meters Bioparma.
The drug, NM-002, is a long-acting, injectable glucagon-like peptide-1 (GLP-1) agonist designed to manipulate gut motility effects in patients with short bowel syndrome by slowing digestive transit time. The drug has already demonstrated safety and extended half-life up to 30 days in a previous study, and it has received orphan drug designation from the FDA.
“In developing NM-002, we've used Amunix's proprietary XTEN technology to extend the half-life of the GLP-1 peptide, which allows the drug to be injected only once or twice per month,” Patrick H. Griffin, MD, FACP, chief medical officer at 9 Meters said in a press release. “This considerably increases convenience for patients and caregivers compared to other GLP-2 drug products on the market for short bowel syndrome, which must be dosed daily.”
The phase 1b/2a trial will take place at Cedars-Sinai in Los Angeles, and the first patient is expected to be dosed July 2020. The company expects topline results in the first half of 2021.
“Not only is SBS a life-threatening disease when untreated, but the current treatment standard of parenteral support is insufficient, as it results in an extremely low quality of life for patients,” John Temperato, president and CEO of 9 Meters, said in the release. “We look forward to developing NM-002 to reduce reliance on intravenous supplementation, and therefore give patients the freedom to live a less restricted lifestyle and reduce their financial burden”
Collapse
Read more about
Click Here to Manage Email Alerts